US FDA accepts Sun Pharma’s NDA for Deuruxolitinib
Deuruxolitinib is being evaluated for treatment of moderate to severe alopecia areata
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.